REGN88

BIOLOGICAL4 trials

Sponsors

Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals

Conditions

Relapsed or Refractory Systemic Light Chain AmyloidosisRheumatoid Arthritis

Phase 1

A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects

CompletedNCT01011959

Regeneron PharmaceuticalsRheumatoid Arthritis

Start: 2008-12-31End: 2009-08-31Updated: 2013-09-30

A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis

CompletedNCT01026519

Regeneron PharmaceuticalsRheumatoid Arthritis

Start: 2008-09-30End: 2009-05-31Updated: 2013-09-30

Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis

CompletedNCT01055899

Regeneron PharmaceuticalsRheumatoid Arthritis

Start: 2008-07-31End: 2009-03-31Updated: 2013-09-30

A Phase 1/2 Study of Linvoseltamab in Patients with Relapsed or Refractory Systemic Light Chain Amyloidosis

RecruitingCTIS2023-507809-34-00

Regeneron Pharmaceuticals Inc.Relapsed or Refractory Systemic Light Chain Amyloidosis

Start: 2024-08-07Target: 27Updated: 2025-09-24

Related Papers

Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis.

2020-11-014 citations